FY2027 EPS Estimates for REGENXBIO Lifted by Leerink Partnrs

REGENXBIO Inc. (NASDAQ:RGNX) – Research analysts at Leerink Partnrs boosted their FY2027 earnings estimates for REGENXBIO in a research report issued to clients and investors on Monday, November 18th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company will post earnings per share of ($1.25) for the year, up from their prior forecast of ($1.87). The consensus estimate for REGENXBIO’s current full-year earnings is ($4.84) per share. Leerink Partnrs also issued estimates for REGENXBIO’s FY2028 earnings at $1.10 EPS.

RGNX has been the subject of a number of other research reports. Barclays lowered their target price on REGENXBIO from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Monday, August 5th. StockNews.com raised REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Chardan Capital reiterated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Wednesday. Raymond James restated an “outperform” rating and issued a $18.00 price target on shares of REGENXBIO in a research report on Thursday, October 10th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $22.00 price target on shares of REGENXBIO in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $35.27.

REGENXBIO Stock Performance

Shares of NASDAQ:RGNX opened at $9.59 on Thursday. REGENXBIO has a 52-week low of $8.53 and a 52-week high of $28.80. The company has a market capitalization of $475.14 million, a PE ratio of -1.91 and a beta of 1.23. The company has a fifty day moving average of $10.31 and a 200-day moving average of $12.12.

Insiders Place Their Bets

In other REGENXBIO news, Director Argeris N. Karabelas sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.11, for a total value of $101,100.00. Following the transaction, the director now directly owns 11,286 shares of the company’s stock, valued at approximately $114,101.46. The trade was a 46.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 13.13% of the company’s stock.

Institutional Trading of REGENXBIO

Hedge funds have recently modified their holdings of the stock. FMR LLC grew its holdings in REGENXBIO by 166.8% in the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 1,656 shares during the period. nVerses Capital LLC boosted its position in shares of REGENXBIO by 183.3% during the 3rd quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 2,200 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of REGENXBIO by 64.3% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 3,720 shares during the period. Diversified Trust Co bought a new stake in REGENXBIO in the 2nd quarter valued at about $121,000. Finally, Arizona State Retirement System raised its stake in REGENXBIO by 20.6% during the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock worth $137,000 after buying an additional 1,997 shares during the period. Institutional investors own 88.08% of the company’s stock.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.